SCYNEXIS, Inc. (SCYX)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$5.03−1.76%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $50.0M
- 52-week range
- $3.53 – $9.12
- 52-week change
- −19.29%
- EPS (trailing)
- −$0.89
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $20.6M (+449.95%)
- Net income
- −$8.6M
- Operating margin
- −78.0%
- Diluted EPS
- −$0.17
From the company’s annual report on SEC EDGAR.
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Headquarters: Jersey City, United States · 18 employees · scynexis.com